HGS and Novartis's hepatitis C candidate Zalbin shows monthly dosing promise
This article was originally published in Scrip
Executive Summary
Human Genome Sciences and Novartis have released interim Phase II data suggesting that monthly-dosing of their hepatitis C treatment candidate Zalbin (albinterferon alfa-2b) achieves comparable results to weekly dosing with Roche's Pegasys (peginterferon alfa-2a) – a current standard of care – in patients with genotypes 2 and 3 of the disease.